Diphenhydramine Hydrochloride Oral Solution USP

Manufacturer
PAI Holdings, LLC dba PAI Pharma | PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma
Effective date
2024-04-05
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
12
Source
full-release
Hydrated at
2026-05-31 21:01:48

Label at a glance#

ProductDIPHENHYDRAMINE HYDROCHLORIDE
Active ingredientDIPHENHYDRAMINE HYDROCHLORIDE
Label structure15 sections

Indications and uses

Diphenhydramine hydrochloride in the oral form is effective for the following indications: For allergic conjunctivitis due to foods; mild, uncomplicated allergic skin manifestations of urticaria and angioedema; amelioration of allergic reactions to blood or plasma; dermatographism; as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been c...

Dosage and administration

DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT. A single oral dose of diphenhydramine hydrochloride is quickly absorbed with maximum activity occurring in approximately one hour. The duration of activity following an average dose of diphenhydramine hydrochloride is from four to six hours. 25 to 50 mg three to four times daily. The nightime sleep aid dosage is 50 mg at bedtim...

Storage and handling

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. Protect from freezing and light.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx ONLY

DESCRIPTION

DESCRIPTION SECTION

Diphenhydramine hydrochloride is an antihistamine drug having the chemical name 2-(diphenylmethoxy)-N,N -dimethylethylamine hydrochloride and has the molecular formula C 17H 21NO•HCI (molecular weight 291.82). It occurs as a white odorless, crystalline powder and is freely soluble in water and alcohol. The structural formula is as follows:

Diphenhydramine chemical structure
Diphenhydramine chemical structure

Each 5 mL contains 12.5 mg of diphenhydramine hydrochloride and alcohol 14% for oral administration.  Inactive Ingredients:  Citric acid, D&C Red No. 33, FD&C Red No. 40, flavoring, purified water, sodium citrate, and sucrose. 

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Diphenhydramine hydrochloride is an antihistamine with anticholinergic (drying) and sedative effects. Antihistamines appear to compete with histamine for cell receptor sites on effector cells.

A single oral dose of diphenhydramine hydrochloride is quickly absorbed with maximum activity occurring in approximately one hour. The duration of activity following an average dose of diphenhydramine hydrochloride is from four to six hours. Diphenhydramine is widely distributed throughout the body, including the CNS. Little, if any, is excreted unchanged in the urine; most appears as the degradation products of metabolic transformation in the liver, which are almost completely excreted within 24 hours.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Diphenhydramine hydrochloride in the oral form is effective for the following indications:

Antihistaminic

SPL UNCLASSIFIED SECTION

For allergic conjunctivitis due to foods; mild, uncomplicated allergic skin manifestations of urticaria and angioedema; amelioration of allergic reactions to blood or plasma; dermatographism; as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.

Motion Sickness

SPL UNCLASSIFIED SECTION

For active and prophylactic treatment of motion sickness.

Antiparkinsonism

SPL UNCLASSIFIED SECTION

For parkinsonism (including drug-induced) in the elderly unable to tolerate more potent agents; mild cases of parkinsonism (including drug-induced) in other age groups; in other cases of parkinsonism (including drug-induced) in combination with centrally acting anticholinergic agents.

SPL UNCLASSIFIED SECTION

Nighttime Sleep-aid.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Use in Neonates or Premature Infants

SPL UNCLASSIFIED SECTION

This drug should not be used in neonates or premature infants.

Use in Nursing Mothers

SPL UNCLASSIFIED SECTION

Because of the higher risk of antihistamines for infants generally, and for neonates and prematures in particular, antihistamine therapy is contraindicated in nursing mothers.

Antihistamines are also contraindicated in the following conditions

SPL UNCLASSIFIED SECTION

Hypersensitivity to diphenhydramine hydrochloride and other antihistamines of similar chemical structure.

WARNINGS

WARNINGS SECTION

Antihistamines should be used with considerable caution in patients with narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, or bladder-neck obstruction.

Use in Pediatric Patients

SPL UNCLASSIFIED SECTION

In pediatric patients, especially, antihistamines in overdosage may cause hallucinations, convulsions, or death. As in adults, antihistamines may diminish mental alertness in pediatric patients. In the young pediatric patient, particularly, they may produce excitation.

Use in the Elderly (approximately 60 years or older)

GERIATRIC USE SECTION

Antihistamines are most likely to cause dizziness, sedation, and hypotension in elderly patients.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Diphenhydramine hydrochloride has an atropine-like action and therefore, should be used with caution in patients with a history of bronchial asthma, increased intraocular pressure, hyperthyroidism, cardiovascular disease or hypertension. Use with caution in patients with lower respiratory disease including asthma.

Information for Patients

INFORMATION FOR PATIENTS SECTION

Patients taking diphenhydramine hydrochloride should be advised that this drug may cause drowsiness and has an additive effect with alcohol. Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc.

Drug Interactions

DRUG INTERACTIONS SECTION

Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.). MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term studies in animals to determine mutagenic and carcinogenic potential have not been performed.

Pregnancy

PREGNANCY SECTION

Pregnancy Category B

TERATOGENIC EFFECTS SECTION

Reproduction studies have been performed in rats and rabbits at doses up to 5 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to diphenhydramine hydrochloride. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Pediatric Use

PEDIATRIC USE SECTION

Diphenhydramine hydrochloride should not be used in neonates and premature infants (see CONTRAINDICATIONS).

Diphenhydramine hydrochloride may diminish mental alertness, or, in the young pediatric patient, cause excitation. Overdosage may cause hallucinations, convulsions, or death (see WARNINGS and OVERDOSAGE ).

See also DOSAGE AND ADMINISTRATION section.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The most frequent adverse reactions are underscored.

  • General: Urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of the mouth, nose and throat.
  • Cardiovascular System: Hypotension, headache, palpitations, tachycardia, extrasystoles.
  • Hematologic System: Hemolytic anemia, thrombocytopenia, agranulocytosis.
  • Nervous System: Sedation,sleepiness,dizziness,disturbed coordination, fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, neuritis, convulsions.
  • GI System: Epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation.
  • GU System: Urinary frequency, difficult urination, urinary retention, early menses.
  • Respiratory System: Thickening of bronchial secretions, tightness of chest or throat and wheezing, nasal stuffiness.

To report SUSPECTED ADVERSE REACTIONS, contact Pharmaceutical Associates, Inc. at 1-800-845-8210 of FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

OVERDOSAGE SECTION

Antihistamine overdosage reactions may vary from central nervous system depression to stimulation. Stimulation is particularly likely in pediatric patients. Atropine-like signs and symptoms, dry mouth; fixed, dilated pupils; flushing and gastrointestinal symptoms may also occur.

If vomiting has not occurred spontaneously, the patient should be induced to vomit. This is best done by having him drink a glass of water or milk after which he should be made to gag. Precaution against aspiration must be taken, especially in infants and children.

If vomiting is unsuccessful, gastric lavage is indicated within 3 hours after ingestion and even later if large amounts of milk or cream were given beforehand. Isotonic or 1/2 isotonic saline is the lavage solution of choice.

Saline cathartics, as milk of magnesia, by osmosis draw water into the bowel and therefore are valuable for their action in rapid dilution of bowel content.

Stimulants should not be used.

Vasopressors may be used to treat hypotension.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT.

A single oral dose of diphenhydramine hydrochloride is quickly absorbed with maximum activity occurring in approximately one hour. The duration of activity following an average dose of diphenhydramine hydrochloride is from four to six hours.

Adults

SPL UNCLASSIFIED SECTION

25 to 50 mg three to four times daily. The nightime sleep aid dosage is 50 mg at bedtime.

Pediatric Patients, other than premature infants and neonates

SPL UNCLASSIFIED SECTION

12.5 to 25 mg three or four times daily. Maximum daily dosage not to exceed 300 mg. For physicians who wish to calculate the dose on the basis of body weight or surface area, the recommended dosage is 5 mg/kg/24 hours or 150 mg/m2/24 hours.

Data are not available on the use of diphenhydramine hydrochloride as a nighttime sleep-aid in children under 12 years.

The basis for determining the most effective dosage regimen will be the response of the patient to medication and the condition under treatment.

In motion sickness, full dosage is recommended for prophylactic use, the first dose to be given 30 minutes before exposure to motion and similar doses before meals and upon retiring for the duration of exposure

STORAGE

STORAGE AND HANDLING SECTION

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. Protect from freezing and light.

HOW SUPPLIED

HOW SUPPLIED SECTION

Each 5 mL of Diphenhydramine Hydrochloride Oral Solution USP (clear purple/red liquid, cinnamon/anise flavor) contains 12.5 mg diphenhydramine hydrochloride with 14% alcohol and is supplied in the following oral dosage forms:

NDC 0121-0489-05:  5 mL unit dose cup

NDC 0121-0489-00:  Case contains 100 unit dose cups of 5 mL (0121-0489-05) packaged in 10  trays of 10 unit dose cups each.

NDC 0121-0978-10:  10 mL unit dose cup

NDC 0121-0978-00:  Case contains 100 unit dose cups of 10 mL (0121-0978-10) packaged in 10  trays of 10 unit dose cups each. 

SPL UNCLASSIFIED SECTION

MANUFACTURED BY

Pharmaceutical
Associates, Inc.

Greenville, SC 29605
www.paipharma.com

R12/18

PRINCIPAL DISPLAY PANEL - 5 mL Unit Dose Cup Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Delivers 5 mL
NDC 0121-0489-05

DIPHENHYDRAMINE HCl
ORAL SOLUTION USP
12.5 mg/5 mL

Alcohol 14%
Package Not Child-Resistant

Store at 20° to 25°C (68° to 77°F).
[See USP Controlled Room Temperature].
Rx ONLY

PHARMACEUTICAL ASSOCIATES, INC.
GREENVILLE, SC 29605

SEE INSERT

5 mL Unit Dose Cup Label
5 mL Unit Dose Cup Label

PRINCIPAL DISPLAY PANEL - 10 mL Unit Dose Cup Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Delivers 10  mL
NDC 0121-0978-10

DIPHENHYDRAMINE  HCl
ORAL SOLUTION USP

25 mg/10 mL

Alcohol 14%
Package Not Child-Resistant

Store at 20° to 25°C (68° to 77°F).
[See USP Controlled Room Temperature].
Rx ONLY

PHARMACEUTICAL ASSOCIATES, INC.
GREENVILLE, SC 29605

SEE INSERT

10 mL Unit Dose Cup Label
10 mL Unit Dose Cup Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1049906diphenhydrAMINE HCl 12.5 MG in 5 mL Oral SolutionPSN12
1049906diphenhydramine hydrochloride 2.5 MG/ML Oral SolutionSCD12
1049906diphenhydramine HCl 12.5 MG per 5 ML Oral SolutionSY12
1049906diphenhydramine hydrochloride 25 MG per 10 ML Oral SolutionSY12
1049906diphenhydramine hydrochloride 50 MG per 20 ML Oral SolutionSY12

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
DIPHENHYDRAMINE Pharmacologic Class Indexing3Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
0e2e0f88-b076-afe1-4bdd-32bca4375becProduct name320250127
d5e51f11-ad28-caa4-4b49-4143974782adProduct name120150831
3e48c9c4-918d-5d23-2f0b-d2398b06be54Product name120140508
865c72dd-0d94-daac-f728-ddd4ded2a79eProduct name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0121-0489-00DIPHENHYDRAMINE HYDROCHLORIDE10 in 1 CASESOLUTION1012
0121-0489-00DIPHENHYDRAMINE HYDROCHLORIDE10 in 1 TRAYSOLUTION1012
0121-0489-05DIPHENHYDRAMINE HYDROCHLORIDE5 mL in 1 CUP, UNIT-DOSESOLUTION512
0121-0978-00DIPHENHYDRAMINE HYDROCHLORIDE10 in 1 TRAYSOLUTION1012
0121-0978-00DIPHENHYDRAMINE HYDROCHLORIDE10 in 1 CASESOLUTION1012
0121-0978-10DIPHENHYDRAMINE HYDROCHLORIDE10 mL in 1 CUP, UNIT-DOSESOLUTION1012

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0121-0489DIPHENHYDRAMINE HYDROCHLORIDE SOLUTION [PAI HOLDINGS, LLC DBA PAI PHARMA]12Current NDC, Legacy NDC, 3 package rows20240410_6fe6fe2d-4405-4e7a-a2ed-5eb367d52842.zip
0121-0978DIPHENHYDRAMINE HYDROCHLORIDE SOLUTION [PAI HOLDINGS, LLC DBA PAI PHARMA]12Current NDC, Legacy NDC, 3 package rows20240410_6fe6fe2d-4405-4e7a-a2ed-5eb367d52842.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0121-0489-00ML - Milliliter0121-0489df5806b5-8583-4282-9225-44936720fd0a12017-07-07
0121-0489-05ML - Milliliter0121-0489c30ba6f4-4825-47bf-b5f5-66b4b6c2ba2412013-02-13
0121-0489-10ML - Milliliter0121-04894742a508-6c04-4846-8a2a-9307f836334f12013-02-13
0121-0978-00ML - Milliliter0121-097850dfe608-97bc-4c81-bf8d-cd2ef338cd1c12017-07-07
0121-0978-10ML - Milliliter0121-0978bf6a2c6b-f01b-4d11-beb4-f418e91f1cac12017-07-07

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
DIPHENHYDRAMINE HYDROCHLORIDEACTIVE INGREDIENTTC2D6JAD402
DIPHENHYDRAMINEACTIVE MOIETY8GTS82S83M2
ALCOHOLINACTIVE INGREDIENT3K9958V90M2
CITRIC ACID MONOHYDRATEINACTIVE INGREDIENT2968PHW8QP2
D&C RED NO. 33INACTIVE INGREDIENT9DBA0SBB0L2
FD&C RED NO. 40INACTIVE INGREDIENTWZB9127XOA2
SODIUM CITRATEINACTIVE INGREDIENT1Q73Q2JULR2
SUCROSEINACTIVE INGREDIENTC151H8M5542
WATERINACTIVE INGREDIENT059QF0KO0R2

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 9 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0121-04890121-0489-05, 0121-0489-00
0121-09780121-0978-10, 0121-0978-00

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 16 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 30 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
D&C RED NO. 33D&C RED NO. 339DBA0SBB0LSOLUTION / ORAL2 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
SUCROSESUCROSEC151H8M554SOLUTION / ORAL70000 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
D&C RED NO. 33D&C RED NO. 339DBA0SBB0LSOLUTION / ORAL2 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
D&C RED NO. 33D&C RED NO. 339DBA0SBB0LSOLUTION / ORAL2 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPSOLUTION / ORAL446 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
D&C RED NO. 33D&C RED NO. 339DBA0SBB0LSOLUTION / ORAL2 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOASOLUTION / ORAL38 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPSOLUTION / ORAL446 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MSOLUTION / ORAL6624 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
SUCROSESUCROSEC151H8M554SOLUTION / ORAL70000 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPSOLUTION / ORAL446 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MSOLUTION / ORAL6624 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MSOLUTION / ORAL6624 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
SUCROSESUCROSEC151H8M554SOLUTION / ORAL70000 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPSOLUTION / ORAL446 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MSOLUTION / ORAL6624 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
D&C RED NO. 33D&C RED NO. 339DBA0SBB0LSOLUTION / ORAL2 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MSOLUTION / ORAL6624 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPSOLUTION / ORAL446 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
SUCROSESUCROSEC151H8M554SOLUTION / ORAL70000 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
SUCROSESUCROSEC151H8M554SOLUTION / ORAL70000 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOASOLUTION / ORAL38 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOASOLUTION / ORAL38 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MSOLUTION / ORAL6624 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOASOLUTION / ORAL38 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOASOLUTION / ORAL38 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOASOLUTION / ORAL38 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
D&C RED NO. 33D&C RED NO. 339DBA0SBB0LSOLUTION / ORAL2 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPSOLUTION / ORAL446 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates
SUCROSESUCROSEC151H8M554SOLUTION / ORAL70000 mgExact identifier — unii+route+dosage form
6 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A087513-001DIPHENHYDRAMINE HYDROCHLORIDEDIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALAARLD, RS1982-02-10

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A087513-001AA

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALAARLD, RS1982-02-1084e616aacf4f…
2026-08-18 06:07:402026-07A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALAARLD, RS1982-02-10caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-10011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-1031067a03dcf5…
2025-08-23 18:47 UTC2025-08A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-106a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-10fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-10b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-1003ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-102680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-105bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-10d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-10d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-1079d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-10301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-101e350fbaab3a…
2024-05-31 18:47 UTC2024-05A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-108072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-105c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-105d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-104b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-1074a2ff9319b5…
2022-03-09 01:35 UTC2022-03A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-10bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-10782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-1087673890dc5c…
2021-03-12 10:30 UTC2021-03A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-105aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-108869cabd3fbd…
2020-11-12 02:37 UTC2020-11A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-10c0c555d07b60…
2019-12-14 00:12 UTC2019-12A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-103f01610625f2…
2019-09-15 20:21 UTC2019-09A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-10b00525d2431f…
2019-07-19 19:46 UTC2019-07A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-10ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-106a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-101c564ffb4f44…
2023-12-20 04:57 UTC2023-12A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-10ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-10a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-109b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-10a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-103f0d92c62455…
2023-05-13 08:27 UTC2023-05A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-10053a50430f4f…
2023-01-26 05:58 UTC2023-01A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-103bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-103a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-10f41ea6bd6efb…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A087513-001AA184e616aacf4f…
2026-08-18 06:07:402026-07A087513-001AA1caaa826d4ba7…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A087513-001AA1a50c72e98297…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
DIPHENHYDRAMINE HYDROCHLORIDEDIPHENHYDRAMINE HYDROCHLORIDEPAI Holdings, LLC dba PAI Pharma6fe6fe2d-4405-4e7a-a2ed-5eb367d528422024-04-05Warnings, Adverse reactionsExact identifier
ndc (package): 0121-0489-00
ndc (package): 0121-0978-10
ndc (package): 0121-0978-00
ndc (package): 0121-0489-05
ndc (product): 0121-0978
ndc (product): 0121-0489
ndc11 (package): 00121097800
ndc11 (package): 00121048905
ndc11 (package): 00121097810
ndc11 (package): 00121048900
spl id: b7eb09fa-58fb-4c3f-ad65-a04965bc52b0
spl set id: 6fe6fe2d-4405-4e7a-a2ed-5eb367d52842

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.